Please Wait.....
Report
PCR Technologies Market by Product (Instruments, Reagents & Consumables, Software), Application (Genotyping, Diagnostic Applications), Technique (Reverse Transcription PCR, qPCR), End-user (Hospital Labs, Diagnostic Labs) - Global Forecasts to 2030
Market Report I 2025-03-01 I 312 Pages I MarketsandMarkets
The PCR technologies market is projected to reach USD 21.89 Billion by 2030 from USD 14.61 in 2024, growing at a CAGR of 7.0% during the forecast period. The market is growing due to numerous factors.Increasing cases of infectious diseases, and regular advancements in PCR technologies drives this market. Rising expenditure in research and development and increase in application of biomarker profiling to detect diseases are other factors. Additionally, the market growth is affected by inclusion of PCR technology with artificial intelligence.
"qPCR to account for largest market share in 2023."
A variant of the Polymerase Chain Reaction (PCR) called quantitative PCR (qPCR), sometimes referred to as real-time PCR, enables the simultaneous amplification and quantification of a particular DNA or RNA sequence. qPCR tracks the reaction in real time as it develops and provides quantitative information on the amount of target nucleic acid, in contrast to traditional PCR, which only identifies the presence of genetic material after the reaction is finished. The market is driven by the rising demand for qPCR instruments, the increasing prevalence of illnesses, and technical advances. Moreover, qPCR is a very specific and sensitive method for identifying and measuring nucleic acids, which makes it necessary for the diagnosis of infectious disorders.
"Diagnostic Laboratories to hold largest share in the market."
Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decrease cost, expedites testing methods, and improve precision and accuracy of diagnosis. Diagnostic labs require PCR identify and diagnose a variety of illnesses. These labs use PCR extensively because of its precision, sensitivity, and speed in diagnosing genetic abnormalities, and infectious diseases.
"North America to register largest share in 2023."
The largest share was hold by North America in 2023. North America comprise US and Canada.
The growth is supported by increase in drug development associated with genomics. Apart from that, government led initiatives and increase in funding and grants supports growth. The region also has strong presence of prominent players who support the growth of this market by carrying out strategic partnerships, collaborations, expansion and acquisitions. Wide application of PCR methods in hospitals and diagnostic labs of this region is also increasing the demand for microfluidics in North America.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3- 20%
- By Designation: C-level-- 35%, Director-level-25%, and Others-40%
- By Region: North America-40%, Europe-30%, Asia Pacific-20%, Latin America- 5%, Middle East and Africa- 5%
Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China) Becton, Dickinson and Company (US) and Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), Hologic Inc. (US),.
Research Coverage
The report comprise segmentation that includes end users, products, applications, and geographic regions. It also discusses the key drivers, restraints, opportunities, and challenges affecting the growth of the PCR technologies market. The research offers stakeholders an assessment of market potential and challenges, with a focus on key players and competitive landscapes. Additionally, micromarkets are assessed according to their overall to the microfluidics sector, growth patterns, and potential. The analysis estimates increase in market segment revenues, focusing on five regions.
Key Benefits of Buying the Report:
This research aids new and existing players in the PCR technologies market to assess the sustainability of their investments by offering detailed information. It offers a dataset to assist in making key decisions. The main advantage of this report includes risk evaluation and offering direction for investment decisions. Market segmentation as per the end-users and geographical areas is offered in the study, that provides analysis and insights. It also provides trends, obstacles, opportunities, and drivers, giving stakeholders the information they need to make strategic decisions.
The report provides the insights on the following pointers:
Analysis of the key drivers, restraints, opportunities, and challenges impacting the PCR technologies market growth: advanced technology and rise in prevalence of infectious diseases ; premium price of devices and strict regulations ; rise in number of diagnostic centers/labs.
Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.
Market Development: Details related to profitable markets: this research discussees the PCR technologies business in numerous regions.
Market Diversification: Detailed understanding of advanced products, unexplored areas, latest developments, and investment in the market.
Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Agilent Technologies, Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 STUDY SCOPE 29
1.3.1 SEGMENTS CONSIDERED 29
1.3.2 INCLUSIONS & EXCLUSIONS 29
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
1.5 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.2 RESEARCH DESIGN 33
2.2.1 SECONDARY RESEARCH 33
2.2.1.1 Key secondary sources 33
2.2.1.2 Key objectives of secondary research 34
2.2.1.3 Key data from secondary sources 35
2.2.2 PRIMARY RESEARCH 35
2.2.2.1 Key primary sources 36
2.2.2.2 Key objectives of primary research 36
2.2.2.3 Key industry insights 37
2.2.2.4 Breakdown of primaries 37
2.3 MARKET SIZE ESTIMATION 38
2.3.1 BOTTOM-UP APPROACH 39
2.3.1.1 Company revenue estimation approach 39
2.3.1.2 Customer-based market estimation 40
2.3.1.3 Top-down approach 41
2.3.1.4 Primary interviews 42
2.3.2 GROWTH FORECAST 42
2.4 DATA TRIANGULATION 43
2.5 MARKET SHARE ASSESSMENT 44
2.6 STUDY ASSUMPTIONS 44
2.7 GROWTH ASSUMPTIONS 44
2.8 RISK ASSESSMENT 46
2.9 RESEARCH LIMITATIONS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 52
4.1 PCR TECHNOLOGIES MARKET OVERVIEW 52
4.2 PCR TECHNOLOGIES MARKET, BY REGION, 2024 VS. 2030 (USD MILLION) 53
4.3 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY AND END USER,
2023 (USD MILLION) 54
4.4 PCR TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
5.2.1 DRIVERS 56
5.2.1.1 Increasing outbreaks of infectious diseases/viral persistence 56
5.2.1.2 Development of miniaturized and portable point-of-care testing devices 57
5.2.1.3 Integration of PCR technology with automation and data analysis tools 58
5.2.1.4 High demand for technologically advanced molecular diagnostics 59
5.2.2 RESTRAINTS 60
5.2.2.1 Premium product pricing 60
5.2.2.2 Dearth of skilled healthcare professionals 61
5.2.3 OPPORTUNITIES 62
5.2.3.1 Increased investments in laboratory infrastructure 62
5.2.3.2 Rising number of applications in rare sequence detection 62
5.2.4 CHALLENGES 63
5.2.4.1 Technical limitations 63
5.2.4.2 Increased pricing pressure on market players 63
5.3 VALUE CHAIN ANALYSIS 64
5.3.1 RESEARCH & DEVELOPMENT 64
5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 64
5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 65
5.4 PORTER'S FIVE FORCES ANALYSIS 66
5.4.1 THREAT OF NEW ENTRANTS 67
5.4.2 THREAT OF SUBSTITUTES 67
5.4.3 BARGAINING POWER OF SUPPLIERS 67
5.4.4 BARGAINING POWER OF BUYERS 67
5.4.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.5 KEY STAKEHOLDERS AND BUYING CRITERIA 68
5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS 68
5.5.2 KEY BUYING CRITERIA 68
5.6 PATENT ANALYSIS 69
5.6.1 LIST OF MAJOR PATENTS 70
5.7 KEY CONFERENCES AND EVENTS, 2024-2025 72
5.8 TRADE DATA ANALYSIS 72
5.8.1 IMPORT DATA FOR HS CODE 3822 73
5.8.2 EXPORT DATA FOR HS CODE 3822 73
5.9 PRICING ANALYSIS 74
5.9.1 AVERAGE SELLING PRICE OF REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2024 74
5.9.2 INDICATIVE PRICING OF REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2024 74
5.9.3 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2022-2024 75
5.9.4 AVERAGE SELLING PRICE OF PCR TECHNOLOGY-BASED PRODUCTS,
BY REGION, 2022-2024 77
5.10 UNMET NEEDS AND KEY PAIN POINTS 78
5.11 ECOSYSTEM ANALYSIS 78
5.12 SUPPLY CHAIN ANALYSIS 80
5.12.1 MANUFACTURING COMPANIES 80
5.12.2 SALES & DISTRIBUTION AGENTS 80
5.12.3 END USERS 80
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81
5.14 TECHNOLOGY ANALYSIS 82
5.14.1 KEY TECHNOLOGIES 82
5.14.1.1 Thermal cyclers 82
5.14.1.2 Real-time quantitative PCR 82
5.14.1.3 Portable and point-of-care PCR 82
5.14.2 COMPLEMENTARY TECHNOLOGIES 83
5.14.2.1 Next-generation sequencing 83
5.14.2.2 Microarrays 83
5.14.2.3 Lab-on-a-chip devices 83
5.14.2.4 Robotics and automation 83
5.14.3 ADJACENT TECHNOLOGIES 83
5.14.3.1 Mass spectrometry 83
5.14.3.2 Single-cell sequencing 84
5.14.3.3 Fluorescence in situ hybridization 84
5.15 REGULATORY LANDSCAPE 84
5.15.1 REGULATORY ANALYSIS 84
5.15.1.1 North America 84
5.15.1.1.1 US 84
5.15.1.1.2 Canada 85
5.15.1.2 Europe 85
5.15.1.3 Asia Pacific 86
5.15.1.3.1 Japan 86
5.15.1.3.2 China 87
5.15.1.3.3 India 87
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
5.16 INVESTMENT AND FUNDING SCENARIO 90
5.17 REIMBURSEMENT SCENARIO ANALYSIS 91
5.18 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET 92
6 PCR TECHNOLOGIES MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
6.2 REAGENTS AND CONSUMABLES 95
6.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET 95
6.3 INSTRUMENTS 96
6.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH 96
6.4 SOFTWARE AND SERVICES 98
6.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE FOR ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH 98
7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE 99
7.1 INTRODUCTION 100
7.2 REAL-TIME PCR 100
7.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH 100
7.3 CONVENTIONAL PCR 103
7.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH 103
7.4 DIGITAL PCR 106
7.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION 106
7.5 REVERSE TRANSCRIPTION PCR 108
7.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH 108
7.6 HOT-START PCR 111
7.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH 111
7.7 MULTIPLEX PCR 114
7.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH 114
7.8 OTHER PCR TECHNIQUES 117
?
8 PCR TECHNOLOGIES MARKET, BY APPLICATION 120
8.1 INTRODUCTION 121
8.2 DIAGNOSTIC APPLICATIONS 122
8.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH 122
8.3 GENOTYPING 123
8.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH 123
8.4 NUCLEIC ACID DETECTION 124
8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH 124
8.5 GENE EXPRESSION ANALYSIS 125
8.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH 125
8.6 NUCLEIC ACID SYNTHESIS 126
8.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH 126
8.7 GENETIC SEQUENCING 127
8.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH 127
8.8 ENVIRONMENTAL APPLICATIONS 128
8.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR 128
8.9 STANDARD VALIDATION/VERIFICATION 129
8.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET 129
8.10 OTHER APPLICATIONS 129
9 PCR TECHNOLOGIES MARKET, BY END USER 131
9.1 INTRODUCTION 132
9.2 HOSPITAL LABORATORIES 132
9.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH 132
9.3 DIAGNOSTIC LABORATORIES 133
9.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH 133
9.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS 134
9.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET 134
9.5 PHARMA-BIOTECH COMPANIES 135
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES 135
9.6 OTHER END USERS 136
?
10 PCR TECHNOLOGIES MARKET, BY REGION 138
10.1 INTRODUCTION 139
10.2 NORTH AMERICA 139
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 140
10.2.2 US 145
10.2.2.1 US to dominate North American PCR technologies market during study period 145
10.2.3 CANADA 147
10.2.3.1 Supportive government initiatives for genomics research to aid market growth 147
10.3 EUROPE 149
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 149
10.3.2 GERMANY 153
10.3.2.1 Presence of well-established pharmaceutical and R&D industry to augment market growth 153
10.3.3 FRANCE 155
10.3.3.1 Increasing investments in life science R&D for infrastructural development to favor market growth 155
10.3.4 UK 157
10.3.4.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth 157
10.3.5 ITALY 159
10.3.5.1 Supportive government policies and high healthcare expenditure to boost market growth 159
10.3.6 SPAIN 161
10.3.6.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth 161
10.3.7 REST OF EUROPE 162
10.4 ASIA PACIFIC 164
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 164
10.4.2 CHINA 169
10.4.2.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth 169
10.4.3 JAPAN 170
10.4.3.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth 170
10.4.4 INDIA 172
10.4.4.1 Presence of large target patient population and high government healthcare expenditure to support market growth 172
10.4.5 AUSTRALIA 174
10.4.5.1 High healthcare expenditure to drive adoption of advanced PCR technologies 174
10.4.6 SOUTH KOREA 176
10.4.6.1 Improved medical tourism and prevalence of chronic diseases to propel market growth 176
10.4.7 REST OF ASIA PACIFIC 178
10.5 LATIN AMERICA 179
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 179
10.5.2 BRAZIL 183
10.5.2.1 Growing focus on proteomics and genomics research to drive market 183
10.5.3 MEXICO 185
10.5.3.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments 185
10.5.4 REST OF LATIN AMERICA 187
10.6 MIDDLE EAST & AFRICA 188
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 189
10.6.2 GCC COUNTRIES 192
10.6.2.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth 192
10.6.3 REST OF MIDDLE EAST & AFRICA 193
11 COMPETITIVE LANDSCAPE 195
11.1 INTRODUCTION 195
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 195
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET 195
11.3 REVENUE ANALYSIS, 2019-2023 197
11.4 MARKET SHARE ANALYSIS, 2023 197
11.4.1 GLOBAL PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2023 197
11.4.2 GLOBAL PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2023 198
11.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2023 199
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 201
11.5.1 STARS 201
11.5.2 EMERGING LEADERS 201
11.5.3 PERVASIVE PLAYERS 201
11.5.4 PARTICIPANTS 202
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 203
11.5.5.1 Company footprint 203
11.5.5.2 Product footprint 204
11.5.5.3 Application footprint 205
11.5.5.4 Technique footprint 206
11.5.5.5 End user footprint 207
11.5.5.6 Region footprint 208
?
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 209
11.6.1 PROGRESSIVE COMPANIES 209
11.6.2 RESPONSIVE COMPANIES 209
11.6.3 DYNAMIC COMPANIES 209
11.6.4 STARTING BLOCKS 209
11.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2023 211
11.6.5.1 DETAILED LIST OF KEY startups/SMEs players 211
11.6.5.2 Competitive benchmarking of key startups/SMEs 212
11.7 COMPANY VALUATION AND FINANCIAL METRICS, 2025 212
11.8 PRODUCT/BRAND COMPARISON 214
11.9 COMPETITIVE SCENARIO 214
11.9.1 PRODUCT LAUNCHES AND APPROVALS 215
11.9.2 DEALS 216
12 COMPANY PROFILES 217
12.1 KEY PLAYERS 217
12.1.1 THERMO FISHER SCIENTIFIC INC. 217
12.1.1.1 Business overview 217
12.1.1.2 Products/Services/Solutions offered 218
12.1.1.3 Recent developments 220
12.1.1.3.1 Product launches and approvals 220
12.1.1.3.2 Deals 221
12.1.1.4 MnM view 222
12.1.1.4.1 Key strengths 222
12.1.1.4.2 Strategic choices 222
12.1.1.4.3 Weaknesses and competitive threats 222
12.1.2 F. HOFFMANN-LA ROCHE LTD. 223
12.1.2.1 Business overview 223
12.1.2.2 Products/Services/Solutions offered 224
12.1.2.3 Recent developments 226
12.1.2.3.1 Product launches and approvals 226
12.1.2.3.2 Deals 227
12.1.2.4 MnM view 227
12.1.2.4.1 Key strengths 227
12.1.2.4.2 Strategic choices 227
12.1.2.4.3 Weaknesses and competitive threats 228
12.1.3 AGILENT TECHNOLOGIES, INC. 229
12.1.3.1 Business overview 229
12.1.3.2 Products/Services/Solutions offered 230
12.1.3.3 Recent developments 232
12.1.3.3.1 Product launches 232
12.1.3.3.2 Other developments 233
12.1.3.4 MnM view 233
12.1.3.4.1 Key strengths 233
12.1.3.4.2 Strategic choices 233
12.1.3.4.3 Weaknesses and competitive threats 233
12.1.4 BIO-RAD LABORATORIES, INC. 234
12.1.4.1 Business overview 234
12.1.4.2 Products/Services/Solutions offered 235
12.1.4.3 Recent developments 238
12.1.4.3.1 Product launches 238
12.1.4.3.2 Deals 238
12.1.4.4 MnM view 239
12.1.4.4.1 Key strengths 239
12.1.4.4.2 Strategic choices 239
12.1.4.4.3 Weaknesses and competitive threats 239
12.1.5 QIAGEN 240
12.1.5.1 Business overview 240
12.1.5.2 Products/Services/Solutions offered 241
12.1.5.3 Recent developments 243
12.1.5.3.1 Product launches and approvals 243
12.1.5.3.2 Deals 244
12.1.5.4 MnM view 245
12.1.5.4.1 Key strengths 245
12.1.5.4.2 Strategic choices 245
12.1.5.4.3 Weaknesses and competitive threats 245
12.1.6 DANAHER CORPORATION 246
12.1.6.1 Business overview 246
12.1.6.2 Products/Services/Solutions offered 247
12.1.6.3 Recent developments 249
12.1.6.3.1 Product approvals 249
12.1.6.3.2 Deals 249
12.1.6.3.3 Expansions 250
12.1.7 ABBOTT 251
12.1.7.1 Business overview 251
12.1.7.2 Products/Services/Solutions offered 252
12.1.7.3 Recent developments 253
12.1.7.3.1 Product approvals 253
12.1.8 TAKARA BIO INC. 254
12.1.8.1 Business overview 254
12.1.8.2 Products/Services/Solutions offered 255
12.1.8.3 Recent developments 256
12.1.8.3.1 Product launches 256
12.1.8.3.2 Deals 257
12.1.9 ANALYTIK JENA GMBH+CO. KG 258
12.1.9.1 Business overview 258
12.1.9.2 Products/Services/Solutions offered 258
12.1.9.3 Recent developments 259
12.1.9.3.1 Product launches 259
12.1.9.3.2 Deals 260
12.1.10 EPPENDORF SE 261
12.1.10.1 Business overview 261
12.1.10.2 Products/Services/Solutions offered 262
12.1.10.3 Recent developments 263
12.1.10.3.1 Product launches and approvals 263
12.1.11 MERCK KGAA 264
12.1.11.1 Business overview 264
12.1.11.2 Products/Services/Solutions offered 265
12.1.12 BIONEER CORPORATION 269
12.1.12.1 Business overview 269
12.1.12.2 Products/Services/Solutions offered 270
12.1.12.3 Recent developments 271
12.1.12.3.1 Other developments 271
12.1.13 REVVITY 272
12.1.13.1 Business overview 272
12.1.13.2 Products/Services/Solutions offered 273
12.1.13.3 Recent developments 274
12.1.13.3.1 Product launches 274
12.1.13.3.2 Other developments 274
12.1.14 BECTON, DICKINSON AND COMPANY 275
12.1.14.1 Business overview 275
12.1.14.2 Products/Services/Solutions offered 276
12.1.14.3 Recent developments 277
12.1.14.3.1 Product launches and approvals 277
12.1.14.3.2 Deals 278
12.1.15 BIOMERIEUX 279
12.1.15.1 Business overview 279
12.1.15.2 Products/Services/Solutions offered 280
12.1.15.3 Recent developments 281
12.1.15.3.1 Product launches and approvals 281
12.1.16 STANDARD BIOTOOLS 282
12.1.16.1 Business overview 282
12.1.16.2 Products/Services/Solutions offered 283
?
12.1.17 HOLOGIC, INC. 285
12.1.17.1 Business overview 285
12.1.17.2 Products/Services/Solutions offered 286
12.1.17.3 Recent developments 287
12.1.17.3.1 Product launches 287
12.1.18 LONZA 288
12.1.18.1 Business overview 288
12.1.18.2 Products/Services/Solutions offered 289
12.1.19 ILLUMINA, INC. 290
12.1.19.1 Business overview 290
12.1.19.2 Products/Services/Solutions offered 291
12.1.20 SANSURE BIOTECH INC. 292
12.1.20.1 Business overview 292
12.1.20.2 Products/Services/Solutions offered 293
12.2 OTHER PLAYERS 294
12.2.1 PROMEGA CORPORATION 294
12.2.2 LIMING BIO 295
12.2.3 TRANSGEN BIOTECH CO., LTD. 296
12.2.4 DAAN GENE CO., LTD. 297
12.2.5 BIOBASE GROUP 298
12.2.6 NIPPON GENETICS EUROPE 299
12.2.7 STILLA 300
12.2.8 GENSCRIPT 301
12.2.9 NEW ENGLAND BIOLABS 302
13 APPENDIX 303
13.1 DISCUSSION GUIDE 303
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 308
13.3 CUSTOMIZATION OPTIONS 310
13.4 RELATED REPORTS 310
13.5 AUTHOR DETAILS 311
TABLE 1 PCR TECHNOLOGIES MARKET: STUDY ASSUMPTIONS 44
TABLE 2 PCR TECHNOLOGIES MARKET: RISK ASSESSMENT 46
TABLE 3 ADVANTAGES AND DISADVANTAGES OF REAL-TIME POINT-OF-CARE RT-PCR DEVICES 57
TABLE 4 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES 66
TABLE 5 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 68
TABLE 6 PCR TECHNOLOGIES MARKET: LIST OF MAJOR PATENTS,
JUNE 2022-DECEMBER 2024 70
TABLE 7 PCR TECHNOLOGIES MARKET: LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025 72
TABLE 8 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019-2023 (USD THOUSAND) 73
TABLE 9 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019?2023 (USD THOUSAND) 73
TABLE 10 INDICATIVE PRICING OF REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER,
2024 (USD) 74
TABLE 11 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION,
2022-2024 (USD) 76
TABLE 12 PCR TECHNOLOGIES MARKET: CURRENT UNMET NEEDS 78
TABLE 13 PCR TECHNOLOGIES MARKET: ROLE IN ECOSYSTEM 79
TABLE 14 US: CLASSIFICATION OF PCR TECHNOLOGY-ASSOCIATED DIAGNOSTIC DEVICES 85
TABLE 15 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
TABLE 16 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 86
TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 86
TABLE 18 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 87
TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 22 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 24 REIMBURSEMENT CODES FOR PCR TESTING, 2024 91
TABLE 25 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 95
TABLE 26 PCR TECHNOLOGIES MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2022-2030 (USD MILLION) 96
TABLE 27 PCR TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION,
2022-2030 (USD MILLION) 97
TABLE 28 PCR TECHNOLOGIES MARKET FOR SOFTWARE AND SERVICES, BY REGION,
2022-2030 (USD MILLION) 98
TABLE 29 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 100
TABLE 30 REAL-TIME PCR MARKET, BY REGION, 2022-2030 (USD MILLION) 101
TABLE 31 REAL-TIME PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 102
TABLE 32 REAL-TIME PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 102
TABLE 33 REAL-TIME PCR MARKET, BY END USER, 2022-2030 (USD MILLION) 103
TABLE 34 CONVENTIONAL PCR MARKET, BY REGION, 2022-2030 (USD MILLION) 104
TABLE 35 CONVENTIONAL PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 104
TABLE 36 CONVENTIONAL PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 105
TABLE 37 CONVENTIONAL PCR MARKET, BY END USER, 2022-2030 (USD MILLION) 105
TABLE 38 DIGITAL PCR MARKET, BY REGION, 2022-2030 (USD MILLION) 106
TABLE 39 DIGITAL PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 107
TABLE 40 DIGITAL PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 107
TABLE 41 DIGITAL PCR MARKET, BY END USER, 2022-2030 (USD MILLION) 108
TABLE 42 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR 109
TABLE 43 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2022-2030 (USD MILLION) 109
TABLE 44 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 110
TABLE 45 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 110
TABLE 46 REVERSE TRANSCRIPTION PCR MARKET, BY END USER,
2022-2030 (USD MILLION) 111
TABLE 47 BENEFITS AND CONSIDERATIONS OF HOT-START PCR TECHNOLOGY 112
TABLE 48 HOT-START PCR MARKET, BY REGION, 2022-2030 (USD MILLION) 112
TABLE 49 HOT-START PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 113
TABLE 50 HOT-START PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 113
TABLE 51 HOT-START PCR MARKET, BY END USER, 2022-2030 (USD MILLION) 114
TABLE 52 MULTIPLEX PCR MARKET, BY REGION, 2022-2030 (USD MILLION) 115
TABLE 53 MULTIPLEX PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 115
TABLE 54 MULTIPLEX PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 116
TABLE 55 MULTIPLEX PCR MARKET, BY END USER, 2022-2030 (USD MILLION) 116
TABLE 56 OTHER PCR TECHNIQUES MARKET, BY REGION, 2022-2030 (USD MILLION) 117
TABLE 57 OTHER PCR TECHNIQUES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 118
TABLE 58 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 118
TABLE 59 OTHER PCR TECHNIQUES MARKET, BY END USER, 2022-2030 (USD MILLION) 119
TABLE 60 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 121
TABLE 61 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022-2030 (USD MILLION) 122
TABLE 62 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION,
2022-2030 (USD MILLION) 123
TABLE 63 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION,
2022-2030 (USD MILLION) 124
TABLE 64 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2022-2030 (USD MILLION) 125
TABLE 65 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION,
2022-2030 (USD MILLION) 126
TABLE 66 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION,
2022-2030 (USD MILLION) 127
TABLE 67 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2022-2030 (USD MILLION) 128
TABLE 68 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION,
BY REGION, 2022-2030 (USD MILLION) 129
TABLE 69 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION,
2022-2030 (USD MILLION) 130
TABLE 70 PCR TECHNOLOGIES MARKET, BY END USER, 2022-2030 (USD MILLION) 132
TABLE 71 PCR TECHNOLOGIES MARKET FOR HOSPITAL LABORATORIES, BY REGION,
2022-2030 (USD MILLION) 133
TABLE 72 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2030 (USD MILLION) 134
TABLE 73 PCR TECHNOLOGIES MARKET FOR ACADEMIC AND GOVERNMENT ORGANIZATIONS, BY REGION, 2022-2030 (USD MILLION) 135
TABLE 74 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2022-2030 (USD MILLION) 136
TABLE 75 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION,
2022-2030 (USD MILLION) 137
TABLE 76 PCR TECHNOLOGIES MARKET, BY REGION, 2022-2030 (USD MILLION) 139
TABLE 77 NORTH AMERICA: KEY MACROINDICATORS 140
TABLE 78 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,
2022-2030 (USD MILLION) 142
TABLE 79 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 142
TABLE 80 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 143
TABLE 81 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 144
TABLE 82 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,
2022-2030 (USD MILLION) 145
TABLE 83 US: KEY MACROINDICATORS 146
TABLE 84 US: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 146
TABLE 85 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 147
TABLE 86 CANADA: KEY MACROINDICATORS 148
TABLE 87 CANADA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 148
TABLE 88 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 149
TABLE 89 EUROPE: KEY MACROINDICATORS 150
TABLE 90 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 150
TABLE 91 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 151
TABLE 92 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 151
TABLE 93 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 152
TABLE 94 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER,
2022-2030 (USD MILLION) 152
TABLE 95 GERMANY: KEY MACROINDICATORS 153
TABLE 96 GERMANY: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 154
TABLE 97 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 154
TABLE 98 FRANCE: KEY MACROINDICATORS 155
TABLE 99 FRANCE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 156
TABLE 100 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 156
TABLE 101 UK: KEY MACROINDICATORS 157
TABLE 102 UK: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 158
TABLE 103 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 158
TABLE 104 ITALY: KEY MACROINDICATORS 159
TABLE 105 ITALY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 160
TABLE 106 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 160
TABLE 107 SPAIN: KEY MACROINDICATORS 161
TABLE 108 SPAIN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 161
TABLE 109 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 162
TABLE 110 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 163
TABLE 111 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 163
TABLE 112 ASIA PACIFIC: MACROECONOMIC INDICATORS 164
TABLE 113 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY,
2022-2030 (USD MILLION) 166
TABLE 114 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 166
TABLE 115 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 167
TABLE 116 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 168
TABLE 117 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER,
2022-2030 (USD MILLION) 168
TABLE 118 CHINA: KEY MACROINDICATORS 169
TABLE 119 CHINA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 169
TABLE 120 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 170
TABLE 121 JAPAN: KEY MACROINDICATORS 171
TABLE 122 JAPAN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 171
TABLE 123 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 172
TABLE 124 INDIA: KEY MACROINDICATORS 173
TABLE 125 INDIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 173
TABLE 126 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 174
TABLE 127 AUSTRALIA: KEY MACROINDICATORS 174
TABLE 128 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 175
TABLE 129 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 175
TABLE 130 SOUTH KOREA: KEY MACROINDICATORS 176
TABLE 131 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 177
TABLE 132 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 177
TABLE 133 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 178
TABLE 134 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 178
TABLE 135 LATIN AMERICA: KEY MACROINDICATORS 179
TABLE 136 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,
2022-2030 (USD MILLION) 180
TABLE 137 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 180
TABLE 138 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 181
TABLE 139 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 182
TABLE 140 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,
2022-2030 (USD MILLION) 183
TABLE 141 BRAZIL: KEY MACROINDICATORS 184
TABLE 142 BRAZIL: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 184
TABLE 143 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 185
TABLE 144 MEXICO: KEY MACROINDICATORS 186
TABLE 145 MEXICO: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 186
TABLE 146 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 187
TABLE 147 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 187
TABLE 148 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 188
TABLE 149 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY REGION,
2022-2030 (USD MILLION) 189
TABLE 150 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 189
TABLE 151 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 190
TABLE 152 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 190
TABLE 153 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022-2030 (USD MILLION) 191
TABLE 154 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER,
2022-2030 (USD MILLION) 191
TABLE 155 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022-2030 (USD MILLION) 192
TABLE 156 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022-2030 (USD MILLION) 193
TABLE 157 REST OF MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION) 194
TABLE 158 REST OF MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION) 194
TABLE 159 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET 195
TABLE 160 PCR TECHNOLOGIES MARKET: DEGREE OF COMPETITION 200
TABLE 161 PCR TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 204
TABLE 162 PCR TECHNOLOGIES MARKET: APPLICATION FOOTPRINT 205
TABLE 163 PCR TECHNOLOGIES MARKET: TECHNIQUE FOOTPRINT 206
TABLE 164 PCR TECHNOLOGIES MARKET: END USER FOOTPRINT 207
TABLE 165 PCR TECHNOLOGIES MARKET: REGION FOOTPRINT 208
TABLE 166 PCR TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES PLAYERS 211
TABLE 167 PCR TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 212
TABLE 168 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021-DECEMBER 2024 215
TABLE 169 PCR TECHNOLOGIES MARKET: DEALS, JANUARY 2021-DECEMBER 2024 216
TABLE 170 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 217
TABLE 171 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 218
TABLE 172 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024 220
TABLE 173 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-DECEMBER 2024 221
TABLE 174 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 223
TABLE 175 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 224
TABLE 176 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021-DECEMBER 2024 226
TABLE 177 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-DECEMBER 2024 227
TABLE 178 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 229
TABLE 179 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 230
TABLE 180 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES,
JANUARY 2021-DECEMBER 2024 232
TABLE 181 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,
JANUARY 2021-DECEMBER 2024 233
TABLE 182 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 234
TABLE 183 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 235
TABLE 184 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES,
JANUARY 2021-DECEMBER 2024 238
TABLE 185 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-DECEMBER 2024 238
TABLE 186 QIAGEN: COMPANY OVERVIEW 240
TABLE 187 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 241
TABLE 188 QIAGEN: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021-DECEMBER 2024 243
TABLE 189 QIAGEN: DEALS, JANUARY 2021-DECEMBER 2024 244
TABLE 190 DANAHER CORPORATION: COMPANY OVERVIEW 246
TABLE 191 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 247
TABLE 192 DANAHER CORPORATION: PRODUCT APPROVALS,
JANUARY 2021-DECEMBER 2024 249
TABLE 193 DANAHER CORPORATION: DEALS, JANUARY 2021- AUGUST 2024 249
TABLE 194 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-DECEMBER 2024 250
TABLE 195 ABBOTT: COMPANY OVERVIEW 251
TABLE 196 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED 252
TABLE 197 ABBOTT: PRODUCT APPROVALS, JANUARY 2021-DECEMBER 2024 253
TABLE 198 TAKARA BIO INC.: COMPANY OVERVIEW 254
TABLE 199 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 255
TABLE 200 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024 256
TABLE 201 TAKARA BIO INC.: DEALS, JANUARY 2021-DECEMBER 2024 257
TABLE 202 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW 258
TABLE 203 ANALYTIK JENA GMBH+CO. KG: PRODUCTS/SERVICES/SOLUTIONS OFFERED 258
TABLE 204 ANALYTIK JENA GMBH+CO. KG: PRODUCT LAUNCHES,
JANUARY 2021-DECEMBER 2024 259
TABLE 205 ANALYTIK JENA GMBH+CO. KG: DEALS, JANUARY 2021-DECEMBER 2024 260
TABLE 206 EPPENDORF SE: COMPANY OVERVIEW 261
TABLE 207 EPPENDORF SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 262
TABLE 208 EPPENDORF SE: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024 263
TABLE 209 MERCK KGAA: COMPANY OVERVIEW 264
TABLE 210 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 265
TABLE 211 BIONEER CORPORATION: COMPANY OVERVIEW 269
TABLE 212 BIONEER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 270
TABLE 213 BIONEER CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2021-DECEMBER 2024 271
TABLE 214 REVVITY: COMPANY OVERVIEW 272
TABLE 215 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 273
TABLE 216 REVVITY: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024 274
TABLE 217 REVVITY: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024 274
TABLE 218 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 275
TABLE 219 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 276
TABLE 220 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024 277
TABLE 221 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021-DECEMBER 2024 278
TABLE 222 BIOMERIEUX: COMPANY OVERVIEW 279
TABLE 223 BIOMERIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED 280
TABLE 224 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021-DECEMBER 2024 281
TABLE 225 STANDARD BIOTOOLS: COMPANY OVERVIEW 282
TABLE 226 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 283
TABLE 227 HOLOGIC, INC.: COMPANY OVERVIEW 285
TABLE 228 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 286
TABLE 229 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024 287
TABLE 230 LONZA: COMPANY OVERVIEW 288
TABLE 231 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 289
TABLE 232 ILLUMINA, INC.: COMPANY OVERVIEW 290
TABLE 233 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 291
TABLE 234 SANSURE BIOTECH INC.: COMPANY OVERVIEW 292
TABLE 235 SANSURE BIOTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 293
TABLE 236 PROMEGA CORPORATION: COMPANY OVERVIEW 294
TABLE 237 LIMINGBIO: COMPANY OVERVIEW 295
TABLE 238 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW 296
TABLE 239 DAAN GENE CO., LTD.: COMPANY OVERVIEW 297
TABLE 240 BIOBASE GROUP: COMPANY OVERVIEW 298
TABLE 241 NIPPON GENETICS EUROPE: COMPANY OVERVIEW 299
TABLE 242 STILLA: COMPANY OVERVIEW 300
TABLE 243 GENSCRIPT: COMPANY OVERVIEW 301
TABLE 244 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 302
FIGURE 1 PCR TECHNOLOGIES MARKET: SEGMENTS CONSIDERED 29
FIGURE 2 PCR TECHNOLOGIES MARKET: YEARS CONSIDERED 30
FIGURE 3 PCR TECHNOLOGIES MARKET: RESEARCH DATA 32
FIGURE 4 PCR TECHNOLOGIES MARKET: RESEARCH DESIGN 33
FIGURE 5 PCR TECHNOLOGIES MARKET: KEY DATA FROM SECONDARY SOURCES 35
FIGURE 6 PCR TECHNOLOGIES MARKET: KEY PRIMARY SOURCES
(DEMAND AND SUPPLY SIDES) 36
FIGURE 7 PCR TECHNOLOGIES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 37
FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 9 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION 38
FIGURE 10 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 39
FIGURE 11 PCR TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION 40
FIGURE 12 PCR TECHNOLOGIES MARKET: BOTTOM-UP APPROACH 41
FIGURE 13 PCR TECHNOLOGIES MARKET: TOP-DOWN APPROACH 41
FIGURE 14 DATA TRIANGULATION METHODOLOGY 43
FIGURE 15 GROWTH PROJECTIONS ON REVENUE IMPACT OF KEY MACROINDICATORS 45
FIGURE 16 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024 VS. 2030 (USD MILLION) 47
FIGURE 17 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024 VS. 2030 (USD MILLION) 48
FIGURE 18 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION) 49
FIGURE 19 PCR TECHNOLOGIES MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 50
FIGURE 20 PCR TECHNOLOGIES MARKET: REGIONAL SNAPSHOT 51
FIGURE 21 INCREASING DEMAND FOR ADVANCED PCR TECHNOLOGIES TO DRIVE MARKET 52
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD 53
FIGURE 23 US AND DIAGNOSTIC LABORATORIES COMMANDED LARGEST MARKET SHARE
IN 2023 54
FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030 55
FIGURE 25 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
FIGURE 26 PCR TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS 65
FIGURE 27 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS 66
FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 68
FIGURE 29 KEY BUYING CRITERIA FOR TOP FOUR END USERS 69
FIGURE 30 PCR TECHNOLOGY-RELATED PATENT APPLICATIONS AND PUBLICATIONS,
JANUARY 2014-DECEMBER 2024 69
FIGURE 31 AVERAGE SELLING PRICE OF REAL-TIME PCR INSTRUMENTS,
BY KEY PLAYER, 2024 74
FIGURE 32 AVERAGE SELLING PRICE OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2022-2024 77
FIGURE 33 PCR TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS 79
FIGURE 34 PCR TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS 81
FIGURE 35 PCR TECHNOLOGIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81
FIGURE 36 INVESTMENT AND FUNDING SCENARIO, 2019-2023 90
FIGURE 37 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 90
FIGURE 38 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 (USD MILLION) 91
FIGURE 39 PCR TECHNOLOGIES MARKET: IMPACT OF AI/GEN AI 93
FIGURE 40 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT 141
FIGURE 41 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT 165
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN PCR TECHNOLOGIES MARKET,
2019-2023 197
FIGURE 43 PCR INSTRUMENTS MARKET SHARE ANALYSIS, 2023 198
FIGURE 44 PCR REAGENTS AND CONSUMABLES MARKET SHARE ANALYSIS, 2023 198
FIGURE 45 PCR SOFTWARE AND SERVICES MARKET SHARE ANALYSIS (2023) 199
FIGURE 46 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 202
FIGURE 47 PCR TECHNOLOGIES MARKET: COMPANY FOOTPRINT 203
FIGURE 48 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 210
FIGURE 49 EV/EBITDA OF KEY VENDORS, 2025 212
FIGURE 50 YTD TOTAL RETURN AND 5-YEAR STOCK BETA VALUE FOR KEY PCR TECHNOLOGY VENDORS 213
FIGURE 51 PCR TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 214
FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 218
FIGURE 53 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 224
FIGURE 54 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 230
FIGURE 55 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 235
FIGURE 56 QIAGEN: COMPANY SNAPSHOT 241
FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT 247
FIGURE 58 ABBOTT: COMPANY SNAPSHOT 252
FIGURE 59 TAKARA BIO INC.: COMPANY SNAPSHOT 255
FIGURE 60 EPPENDORF SE: COMPANY SNAPSHOT 262
FIGURE 61 MERCK KGAA: COMPANY SNAPSHOT 265
FIGURE 62 BIONEER CORPORATION: COMPANY SNAPSHOT 269
FIGURE 63 REVVITY: COMPANY SNAPSHOT 273
FIGURE 64 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 276
FIGURE 65 BIOMERIEUX: COMPANY SNAPSHOT 280
FIGURE 66 STANDARD BIOTOOLS: COMPANY SNAPSHOT 283
FIGURE 67 HOLOGIC, INC.: COMPANY SNAPSHOT 286
FIGURE 68 LONZA: COMPANY SNAPSHOT 289
FIGURE 69 ILLUMINA, INC.: COMPANY SNAPSHOT 291
FIGURE 70 SANSURE BIOTECH INC.: COMPANY SNAPSHOT 292
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security